

Remarks

A Request for Continuing Examination has been filed herewith in view of the
5 Final Office Action. The Examiner is requested to examine the claims as amended
above in view of the following remarks.

Claims 1-18 were previously cancelled. Claims 19-22 have been amended so
as to conform with the restriction requirement. Claim 22 is directed to the elected
10 species/invention, viz., compound 73 of Figure 2. Claims 23-26 have been withdrawn
as being not directed to the elected species/invention. Claims 23-26 have also been
amended so as to enhance their clarity.

An examination of Claim 19-22 is respectfully requested.
15

Restriction Requirement:

Claims 19-22 were withdrawn by the examiner as being drawn to non-elected
inventions. Applicant has amended claims 19-22 to bring the claims into conformance
with the elected invention. More particularly, the use of the term “-OP” has been
20 eliminated as being redundant with other elements within the Markush groups, e.g.,
“-O(C₁-C₆ alkyl)”. Also, the claims have been restructured so that they are no longer
improvement claims. This should facilitate the examination process.

Applicant traverses the Examiner's restriction/election requirement. Compound
25 19 is a genus claim because it is directed to the presence of an hydroxyl or alkyl ether
substituent at one or more of three adjacent carbons on a pyrrolidine ring. The
pyrrolidine ring is of a type having a *t*-butyl amide substituent on the fourth carbon.

Summary:

5 Applicant requests that the Examiner examine claims 19-22, as amended, and to provide us with a notice of allowance with respect to these claims.

Respectfully submitted,

10



15

Donald G. Lewis
Reg. No. 28,636
The Scripps Research Institute
10550 N. Torrey Pines Road TPC-8
San Diego, CA 92037
June 17, 2004
20 (858) 784-2937